United Therapeutics news
ΓUnited Therapeutics
24.05.22
United Therapeutics
FDA has approved a dry powder inhaler, treprostinil, under the brand name Tyvaso DPI from United Therapeutics. The drug is for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
FDA has approved a dry powder inhaler, treprostinil, under the brand name Tyvaso DPI from United Therapeutics. The drug is for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Source: 
ir.unither.com
ir.unither.com
0
0
04.05.22
United Therapeutics
United Therapeutics' GAAP net income for 3 months of 2022 was $239.9 million, up 8.5 times from $28.3 million in the previous year. Revenue increased by 19.2% to $451.9 million compared to $379.1 million a year earlier.
United Therapeutics' GAAP net income for 3 months of 2022 was $239.9 million, up 8.5 times from $28.3 million in the previous year. Revenue increased by 19.2% to $451.9 million compared to $379.1 million a year earlier.
Source: ir.unither.com
ir.unither.com
0
0
24.02.22
United Therapeutics
United Therapeutics' GAAP net income for 2021 was $475.8 million, down 7.6% from $514.8 million in the previous year. Revenues increased 13.7% to $1.686 billion from $1.483 billion a year earlier.
United Therapeutics' GAAP net income for 2021 was $475.8 million, down 7.6% from $514.8 million in the previous year. Revenues increased 13.7% to $1.686 billion from $1.483 billion a year earlier.
Source: ir.unither.com
ir.unither.com
0
0
03.11.21
United Therapeutics
United Therapeutics' GAAP net income for 9M 2021 was $363.6 million, down 12.6% from $416 million in the previous year. Revenue increased 15.7% to $1.27 billion compared to $1.098 billion a year earlier.
United Therapeutics' GAAP net income for 9M 2021 was $363.6 million, down 12.6% from $416 million in the previous year. Revenue increased 15.7% to $1.27 billion compared to $1.098 billion a year earlier.
Source: d18rn0p25nwr6d.cloudfront.net
0
0
01.10.21
United Therapeutics
United Therapeutics changed its legal form to Public Benefit Corporation. United became the first public pharmaceutical company registered as a PBC. This legal form of organization allows to indicate in the charter the purpose of its activity not only to make profit, but also to impact the life of society for the better.
United Therapeutics changed its legal form to Public Benefit Corporation. United became the first public pharmaceutical company registered as a PBC. This legal form of organization allows to indicate in the charter the purpose of its activity not only to make profit, but also to impact the life of society for the better.
Source: ir.unither.com
ir.unither.com
0
0
04.08.21
United Therapeutics
United Therapeutics' GAAP net income for 6 months 2021 was $200.9 million, down 17.9% from $244.8 million in the previous year. Revenue increased 14.9% to $825.6 million from $718.3 million a year earlier.
United Therapeutics' GAAP net income for 6 months 2021 was $200.9 million, down 17.9% from $244.8 million in the previous year. Revenue increased 14.9% to $825.6 million from $718.3 million a year earlier.
Source: s1.q4cdn.com
0
0
05.05.21
United Therapeutics
United Therapeutics' GAAP net income for 3 months of 2021 was $28.3 million, down 4.9 times from $137.7 million in the previous year. Revenue increased 6.4% to $379.1 million from $356.3 million a year earlier.
United Therapeutics' GAAP net income for 3 months of 2021 was $28.3 million, down 4.9 times from $137.7 million in the previous year. Revenue increased 6.4% to $379.1 million from $356.3 million a year earlier.
Source: ir.unither.com
ir.unither.com
0
0
01.04.21
United Therapeutics
United Therapeutics has received FDA approval for Tyvaso dry inhalation powder to treat patients with pulmonary hypertension associated with interstitial lung disease.
United Therapeutics has received FDA approval for Tyvaso dry inhalation powder to treat patients with pulmonary hypertension associated with interstitial lung disease.
Source: ir.unither.com
ir.unither.com
0
0
24.02.21
United Therapeutics
United Therapeutics' GAAP net income for 2020 was $514.8 million, compared to a loss of $104.5 million in the previous year. Revenues increased 2.3% to $1.483 billion from $1.449 billion a year earlier.
United Therapeutics' GAAP net income for 2020 was $514.8 million, compared to a loss of $104.5 million in the previous year. Revenues increased 2.3% to $1.483 billion from $1.449 billion a year earlier.
Source: ir.unither.com
ir.unither.com
0
0
28.10.20
United Therapeutics
United Therapeutics' net profit under GAAP for 9 months of 2020 was $416 million, against a loss of $157.1 million in the previous year. Revenue decreased by 3.5% to $1.098 billion compared to $1.138 billion a year earlier.
United Therapeutics' net profit under GAAP for 9 months of 2020 was $416 million, against a loss of $157.1 million in the previous year. Revenue decreased by 3.5% to $1.098 billion compared to $1.138 billion a year earlier.
Source: s1.q4cdn.com
0
0
English (US) 